Read by QxMD icon Read

HCC Recurrence

Woo-Hyoung Kang, Ki-Hun Kim, Dong-Hwan Jung, Gil-Chun Park, Seok-Hwan Kim, Hwui-Dong Cho, Sung-Gyu Lee
BACKGROUND: Liver resection is a potentially curative therapy for hepatocellular carcinoma (HCC). LLR is a newly developed and safe technique associated with shorter hospital stay, less pain, better cosmetic outcomes, and similar complication rates as open surgery; however, data on its long-term outcomes remain scarce. METHODS: We retrospectively examined the clinical and follow-up data of 234 patients who underwent LLR (performed by a single surgeon in all cases) for the primary treatment of HCC between July 2007 and December 2015 at Asan Medical Center...
April 24, 2018: Surgical Endoscopy
Fei Ji, Zhi-Heng Zhang, Yi Zhang, Shun-Li Shen, Qing-Hua Cao, Long-Juan Zhang, Shao-Qiang Li, Bao-Gang Peng, Li-Jian Liang, Yun-Peng Hua
BACKGROUND: Embryonic Liver Fodrin (ELF) is an adaptor protein of transforming growth factor (TGF-β) signaling cascade. Disruption of ELF results in mislocalization of Smad3 and Smad4, leading to compromised TGF-β signaling. c-Myc is an important oncogenic transcription factor, and the disruption of TGF-β signaling promotes c-Myc-induced hepatocellular carcinoma (HCC) carcinogenesis. However, the prognostic significance of c-Myc in HCC is less understood METHODS: The expression of c-Myc protein and mRNA were measured by immunohistochemistry (IHC) and qRT- PCR, respectively...
April 24, 2018: BMC Cancer
Kangshun Zhu, Jingjun Huang, Lisha Lai, Wensou Huang, Mingyue Cai, Jingwen Zhou, Yongjian Guo, Junwei Chen
Purpose To determine the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, S-TACE-RFA) in patients with medium or large (range, 3.1-7.0 cm in diameter) hepatocellular carcinoma (HCC). Materials and Methods This retrospective study evaluated the medical records of consecutive patients with medium or large HCC who underwent S-TACE-RFA or combined TACE and RFA (hereafter, TACE-RFA) from January 2010 to December 2014. Sorafenib was started 3-5 days after TACE, and RFA was performed 1-2 weeks after TACE...
April 24, 2018: Radiology
Erhua Yao, Jinghong Chen, Xiaofang Zhao, Yinyan Zheng, Xianheng Wu, Fei Han, Hecheng Huang, Ping Liang, Jianmin Liu, Fasheng Wu, Lianxing Lin
Aim: To evaluate the efficacy and toxicity of hypofractionated stereotactic body radiotherapy (SBRT) for patients with recurrent or residual hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). Methods: Between June 2008 and July 2015, thirty-three patients with HCC were treated by SBRT. There were 63 lesions in 33 patients. A total dose of 39-45 Gy/3-5 fractions was delivered to the 70-80% isodose line. Results: Objective response rate (CR + PR) was 84...
2018: BioMed Research International
Ke Chen, Yu Pan, Bin Zhang, Xiao-Long Liu, Hendi Maher, Xue-Yong Zheng
Objective: To present a meta-analysis of high-quality case-matched studies comparing laparoscopic (LH) and open hepatectomy (OH) for hepatocellular carcinoma (HCC). Methods: Studies published up to September 2017 comparing LH and OH for HCC were identified. Selection of high-quality, nonrandomized comparative studies (NRCTs) with case-matched design was based on a validated tool (Methodological Index for Nonrandomized Studies) since no randomized controlled trials (RCTs) were published...
2018: Canadian Journal of Gastroenterology & Hepatology
Quirino Lai, Fabio Melandro, Zoe Larghi Laureiro, Francesco Giovanardi, Stefano Ginanni Corradini, Flaminia Ferri, Redan Hassan, Massimo Rossi, Gianluca Mennini
AIM: To perform a systematic review and meta-analysis on platelet-to-lymphocyte ratio (PLR) as a risk factor for post-transplant hepatocellular cancer (HCC) recurrence. METHODS: A systematic literature search was performed using PubMed. Participants of any age and sex, who underwent liver transplantation for HCC were considered following these criteria: (1) studies comparing pre-transplant low vs high PLR values; (2) studies reporting post-transplant recurrence rates; and (3) if more than one study was reported by the same institute, only the most recent was included...
April 21, 2018: World Journal of Gastroenterology: WJG
Xian-Yang Qin, Harukazu Suzuki, Masao Honda, Hikari Okada, Shuichi Kaneko, Ikuyo Inoue, Etsuko Ebisui, Kosuke Hashimoto, Piero Carninci, Keita Kanki, Hideki Tatsukawa, Naoto Ishibashi, Takahiro Masaki, Tomokazu Matsuura, Hiroyuki Kagechika, Kan Toriguchi, Etsuro Hatano, Yohei Shirakami, Goshi Shiota, Masahito Shimizu, Hisataka Moriwaki, Soichi Kojima
Hepatocellular carcinoma (HCC) is a highly lethal cancer that has a high rate of recurrence, in part because of cancer stem cell (CSC)-dependent field cancerization. Acyclic retinoid (ACR) is a synthetic vitamin A-like compound capable of preventing the recurrence of HCC. Here, we performed a genome-wide transcriptome screen and showed that ACR selectively suppressed the expression of MYCN, a member of the MYC family of basic helix-loop-helix-zipper transcription factors, in HCC cell cultures, animal models, and liver biopsies obtained from HCC patients...
April 23, 2018: Proceedings of the National Academy of Sciences of the United States of America
Aventinus Nörthen, Thomas Asendorf, Hoen-Oh Shin, Jan B Hinrichs, Thomas Werncke, Arndt Vogel, Martha M Kirstein, Frank K Wacker, Thomas Rodt
PURPOSE: Parametric response mapping (PRM) is a novel image-analysis technique applicable to assess tumor viability and predict intrahepatic recurrence of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). However, to date, the prognostic value of PRM for prediction of overall survival in HCC patients undergoing TACE is unclear. The objective of this explorative, single-center study was to identify cut-off values for voxel-specific PRM parameters that predict the post TACE overall survival in HCC patients...
April 21, 2018: Abdominal Radiology
Jens Ziegle, Chloé Audigier, Johannes Krug, Ghazanfar Ali, Younsu Kim, Emad M Boctor, Michael Friebe
PURPOSE: Radiofrequency (RF) ablation with mono- or bipolar electrodes is a common procedure for hepatocellular carcinoma (HCC) with a low rate of recurrence for small size tumors. For larger lesions and/or non-round/ellipsoid shapes RF ablation has some limitations and generally does not achieve comparable success rates to microwave ablation or high-intensity focused ultrasound therapies. MATERIALS AND METHODS: To shape RF ablations for matching a tumor size and geometry, we have developed an electronic channel switch box for two bipolar needles that generates multiple selectable ablation patterns...
April 20, 2018: International Journal of Computer Assisted Radiology and Surgery
Zhe Li, Jiwei Zhang, Xinyang Liu, Shengli Li, Qifeng Wang, Di Chen, Zhixiang Hu, Tao Yu, Jie Ding, Jinjun Li, Ming Yao, Jia Fan, Shenglin Huang, Qiang Gao, Yingjun Zhao, Xianghuo He
Recurrent chromosomal aberrations have led to the discovery of oncogenes or tumour suppressors involved in carcinogenesis. Here we characterized an oncogenic long intergenic non-coding RNA in the frequent DNA-gain regions in hepatocellular carcinoma (HCC), LINC01138 (long intergenic non-coding RNA located on 1q21.2). The LINC01138 locus is frequently amplified in HCC; the LINC01138 transcript is stabilized by insulin like growth factor-2 mRNA-binding proteins 1/3 (IGF2BP1/IGF2BP3) and is associated with the malignant features and poor outcomes of HCC patients...
April 20, 2018: Nature Communications
Wanyong Chen, Chenhao Zhou, Wentao Zhang, Manar Atyah, Yirui Yin, Lei Guo, Weiguo Tang, Qiongzhu Dong, Qinghai Ye, Ning Ren
Introduction: The WW domain-containing oxidoreductase (WWOX), widely expressed in human tissues, is considered as a tumor suppressor gene and plays an important role in the incidence and progression of human cancer, HCC included. This study was to investigate the correlation between single nucleotide polymorphisms (SNPs) of the WWOX gene and the prognosis of hepatocellular carcinoma (HCC) patients. Materials and Methods: After a total of 152 HCC patients were recruited, 8 cases with tumor recurrence within 2-years after operation and 8 cases without recurrence were selected randomly for SNP genotyping and screening using Affymetrix Array 6...
2018: Journal of Cancer
Eunkyong Ko, Jong-Seo Kim, Soomi Ju, Hyun-Wook Seo, Yeonji Chang, Jung-Ah Kang, Sung-Gyoo Park, Guhung Jung
DKC1 is a conserved gene encoding the RNA-binding protein, dyskerin pseudouridine synthase 1, which is an essential component of the telomerase holoenzyme. DKC1 upregulation is frequently observed in many different human cancers including hepatocellular carcinoma (HCC); however, its regulatory mechanisms still remain unclear. Thus, we investigated the regulatory mechanism of DKC1 in HCC progression. We found that protein-disulfide isomerase-associated 3 (PDIA3) interacted with the DKC1 regulatory DNA in HCC cells, but not in HCC cells with elevated reactive oxygen species (ROS) levels, using liquid chromatography tandem-mass spectrometry analysis after isolating the DKC1 regulatory region binding proteins...
April 19, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Tong Zhang, Wei Liu, Wei Meng, Hui Zhao, Qing Yang, Shi-Jie Gu, Cui-Cui Xiao, Chang-Chang Jia, Bin-Sheng Fu
Introduction: Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancer. Although great progress has been made on HCC molecular mechanism and therapy techniques, the prognosis of HCC patient is poor due to high metastasis and recurrence. Materials and methods: Expression of miR-542-3p was quantified by quantitative real-time PCR (qRT-PCR). The role of miR-542-3p in HCC metastasis was examined using transwell and 3D-culture assay. qRT-PCR, Western blotting and luciferase reporter assay were used to elucidate the mechanisms of miR-542-3p-mediated cancer metastasis...
2018: OncoTargets and Therapy
Chenchen Wang, Ying Tong, Yankai Wen, Jie Cai, Han Guo, Lifeng Huang, Min Xu, Mingxuan Feng, Xiaosong Chen, Jianjun Zhang, Hailong Wu, Xiaoni Kong, Qiang Xia
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Increased lipogenesis has been reported to play a critical role in HCC progression. However, the underlying mechanism contributing to lipogenesis increase in HCC remains elusive. Here, we show that hepatocellular carcinoma-associated protein TD26 (TD26) was highly expressed in HCC tumor tissues compared to matched normal tissues. From the clinicopathologic analyses of two independent HCC cohorts, we demonstrate that TD26 expression was positively correlated with tumor size and was an independent predictor of overall survival (OS) and recurrence free survival (RFS) in HCC patients...
April 16, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Derek J Erstad, Bryan C Fuchs, Kenneth K Tanabe
Molecular characterization of hepatocellular carcinoma (HCC) has greatly improved our understanding of disease pathogenesis. Mutational analysis, RNA and microRNA expression profiling, and epigenetic characterization have revealed common aberrations in oncogenes and tumor suppressors that correlate with disease biology and serve as a guide for the rational design of targeted therapies. These approaches have also led to the discovery of novel targets, including mutations in isocitrate dehydrogenase and chromatin remodeling enzymes...
April 17, 2018: Cancer
Ke-Vin Chang, Jin-De Chen, Wei-Ting Wu, Kuo-Chin Huang, Chia-Tzu Hsu, Der-Sheng Han
Background: Hepatocellular carcinoma (HCC) has multiple prognostic factors, and there is an increase in knowledge about the body composition and physical status of patients with HCC. The present meta-analysis aimed to explore whether loss of skeletal muscle mass is associated with mortality and tumor recurrence in patients with HCC. Method: A systematic search was conducted for published literature using PubMed, Embase, and Scopus. We included cohort or case-control studies investigating patients with HCC...
March 2018: Liver Cancer
Sabela Lens, María García-Eliz, Inmaculada Fernández, Lluis Castells, Martin Bonacci, Antoni Mas, Gonzalo Crespo, María Buti, Martín Prieto, Xavier Forns
BACKGROUND AND AIM: The combination of hepatitis B immunoglobulin (HBIG) and a nucleos(t)ide analogs (NA) has markedly reduced the rate of hepatitis B (HBV) recurrence after liver transplantation (LT); however, the optimal duration of HBIG has not been clarified. This lack of consensus perpetuates the use of different strategies. The aim of this study was to evaluate the risk factors associated to HBV recurrence after LT in a large cohort of patients under different HBIG regimens. METHODS: Retrospective multicenter analysis of HBV-related LT recipients receiving combined prophylaxis (HBIG+NA)...
April 16, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Junyi Shen, Jiaye Liu, Chuan Li, Tianfu Wen, Lvnan Yan, Jiayin Yang
The effects of serum hepatitis B e antigen (HBeAg) on the prognosis of hepatocellular carcinoma (HCC) patients after hepatectomy remain controversial. Our aim was to explore the prognostic significance of serum HBeAg on the prognosis of HCC patients using a propensity matching model. Between January 2009 and March 2015, 953 patients with HCC who underwent hepatectomy in West China Hospital were analyzed. Propensity matching analysis was applied and survival analysis was performed using the Kaplan-Meier method...
April 16, 2018: Journal of Viral Hepatitis
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Yukio Osaki, Yuji Kojima, Ryo Nakata, Tohru Goto, Akahane Takehiro, Hiroyuki Kimura, Akeri Mitsuda, Chiharu Kawanami, Yasushi Uchida, Chikara Ogawa, Atsunori Kusakabe, Ryuichi Narita, Yasushi Ide, Takehiko Abe, Keiji Tsuji, Tadashi Kitamura, Kazuhiko Okada, Tetsuro Sohda, Masaya Shigeno, Takashi Satou, Namiki Izumi
BACKGROUND AND AIM: This study aimed to elucidate whether interferon (IFN)-free direct-acting antiviral (DAA) therapy for hepatitis C after curative treatment of hepatocellular carcinoma (HCC) promotes HCC recurrence in a real-world large-scale cohort. METHODS: This multicenter study was conducted by the Japanese Red Cross Hospital Liver Study Group. This retrospective study analyzed 516 patients who underwent antiviral treatment for hepatitis C with either IFN (n = 148) or IFN-free DAA (n = 368) after curative HCC treatment; 78 IFN-treated patients and 347 IFN-free DAA-treated patients achieved sustained virological response (SVR)...
2018: PloS One
Masaru Kubota, Yasuji Hashimoto, Hiroki Imamura, Yuriko Yagi, Takashi Noma, Yukako Mokutani, Kenichi Nagai, Hajime Hirose, Yoshihito Ide, Jin Matsuyama, Yukio Fukushima, Yousuke Nishioka, Masashi Takeda, Shigeyuki Tamura, Yo Sasaki
Hepatocellular carcinoma(HCC)is not commonly observed with bile duct thrombosis.Here, we report a case of HCC with bile thrombi that extended to the liver hilum.The patient was a 61-year-old man who visited us due to untreated type B hepatitis.He underwent screening with a CT scan that revealed LDA on the right posterior lobe of his liver with infiltration of the bile duct.Generally, bile resection and reconstruction should be considered for curative resection for bile thrombi; however, we attempted to conserve the common bile duct to preserve the options of percutaneous therapy in case of tumor recurrence...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"